What changed: Sarcomas (soft tissue, bone, GIST)
Every dated change on the records linked to Sarcomas (soft tissue, bone, GIST), newest first: approvals and regulatory steps on its medicines, trials that reported, guideline versions, milestones, and when this page itself was checked. Dates come from the records; none is inferred. Orientation, not medical advice.
September 2026 · 1
2026 · 9
- 2026GuidelineSarcomas (soft tissue, bone, GIST)Guideline NCCN 2026 / ESMO 2021: Localised high-risk soft-tissue sarcoma (grade 3, >5 cm, deep)
Neoadjuvant anthracycline-ifosfamide × 3 (ISG-STS 1001) ± preoperative radiotherapy, then wide resection; regional hyperthermia with chemotherapy where available (EORTC 62961). (NCCN Category 2A (neoadjuvant chemotherapy for high-risk), ESMO-MCBS A (ISG-STS 1001))
- 2026GuidelineSarcomas (soft tissue, bone, GIST)Guideline NCCN 2026: Advanced soft-tissue sarcoma, first line
Doxorubicin 75 mg/m2 (single agent) or doxorubicin-ifosfamide for symptomatic/rapid disease (EORTC 62012: PFS but not OS benefit); histotype exceptions: trabectedin or gemcitabine-docetaxel for leiomyosarcoma, paclitaxel for angiosarcoma. Adding olaratumab to doxorubicin gave no survival benefit (ANNOUNCE). (NCCN Category 1 (anthracycline-based))
- 2026GuidelineSarcomas (soft tissue, bone, GIST)Guideline NCCN 2026: Advanced soft-tissue sarcoma, later lines
Trabectedin (L-sarcomas), eribulin (liposarcoma), pazopanib (non-adipocytic), gemcitabine-docetaxel, dacarbazine; pembrolizumab for alveolar soft-part sarcoma or UPS; larotrectinib for NTRK fusion; afami-cel or lete-cel for MAGE-A4/NY-ESO-1+ synovial sarcoma and MRCLS. (NCCN Category 2A)
- 2026GuidelineSarcomas (soft tissue, bone, GIST)Guideline NCCN 2026: Desmoid tumour
Active surveillance first (many regress); nirogacestat (DeFi) for progressing symptomatic disease; sorafenib alternative; surgery only for select sites; cryoablation for extra-abdominal tumours. (NCCN Category 1 (nirogacestat))
- 2026GuidelineSarcomas (soft tissue, bone, GIST)Guideline NCCN 2026: GIST, advanced
Imatinib 400 mg (800 mg for exon 9) → sunitinib → regorafenib → ripretinib (INVICTUS); avapritinib for PDGFRA D842V; ctDNA KIT genotyping to choose ripretinib vs sunitinib second line (INSIGHT); surgery for oligoprogression. (NCCN Category 1 sequence)
- 2026GuidelineSarcomas (soft tissue, bone, GIST)Guideline NCCN 2026: GIST, localised
Resection; adjuvant imatinib 3 years for high risk (SSGXVIII), longer under study; none for PDGFRA D842V or SDH-deficient (imatinib-insensitive). (NCCN Category 1 (imatinib 3 years, high-risk), ESMO-MCBS A)
- 2026GuidelineSarcomas (soft tissue, bone, GIST)Guideline NCCN 2026: Tenosynovial giant cell tumour
Surgery for localised disease; vimseltinib (MOTION) or pexidartinib (REMS for hepatotoxicity) for diffuse disease not amenable to surgery. (NCCN Category 2A)
- 2026GuidelineSarcomas (soft tissue, bone, GIST)Guideline NCCN Soft Tissue Sarcoma 2026: Localised extremity/trunk soft-tissue sarcoma, low grade
Wide resection (limb-salvage) ± radiotherapy for margins or size >5 cm; observation thereafter. (NCCN Category 1 (surgery ± RT))
- 2026MilestoneAfamitresgene autoleucelTazemetostat withdrawn worldwide (9 March); afami-cel full approval and age ≥12 (June); INSIGHT positive
A milestone in how this cancer is treated.
2025 · 1
August 2024 · 1
2024 · 5
- 2024ApprovalAfamitresgene autoleucelAfamitresgene autoleucel approved in US
Advanced MAGE-A4+ synovial sarcoma, HLA-A*02+ (age ≥12 from 2026)
- 2024Trial resultIGNYTE-ESOIGNYTE-ESO reported
ORR 42%.
- 2024Trial resultMOTIONMOTION reported
ORR 40% vs 0%.
- 2024MilestoneAfamitresgene autoleucelAfami-cel: first TCR-T for a solid tumour
A milestone in how this cancer is treated.
- 2024MilestoneAfamitresgene autoleucelAfami-cel: first TCR-T for a solid tumour; MOTION positive; IGNYTE-ESO reports
A milestone in how this cancer is treated.
2023 · 1
May 2022 · 1
2022 · 2
2021 · 1
May 2020 · 1
January 2020 · 1
2020 · 6
- 2020ApprovalRipretinibRipretinib approved in US
Advanced GIST after ≥3 prior kinase inhibitors including imatinib
- 2020ApprovalTazemetostatTazemetostat approved in US
Epithelioid sarcoma; relapsed FL (EZH2-mutant after 2 lines; wild-type without alternatives)
- 2020Trial resultEuro Ewing 2012Euro Ewing 2012 reported
EFS HR 0.
- 2020Trial resultINVICTUSINVICTUS reported
PFS HR 0.
- 2020Trial resultVOYAGERVOYAGER reported
PFS HR 1.
- 2020MilestoneRipretinibRipretinib (INVICTUS) and avapritinib (D842V) approved; tazemetostat approved for epithelioid sarcoma
A milestone in how this cancer is treated.
2019 · 4
- 2019ApprovalAnlotinibAnlotinib approved in China
Advanced soft tissue sarcoma after chemotherapy; small cell lung cancer after at least two lines
- 2019ApprovalNBTXR3 (hafnium oxide nanoparticles)NBTXR3 (hafnium oxide nanoparticles) approved in EU
CE mark: locally advanced soft-tissue sarcoma of the limb or trunk wall, with preoperative radiotherapy
- 2019Trial resultANNOUNCEANNOUNCE reported
OS HR 1.
- 2019MilestoneANNOUNCEANNOUNCE fails; olaratumab withdrawn
A milestone in how this cancer is treated.
2017 · 2
2016 · 2
2015 · 1
2014 · 1
2012 · 3
- 2012ApprovalPazopanibPazopanib approved in US
Advanced non-adipocytic soft-tissue sarcoma after chemotherapy
- 2012Trial resultSSGXVIII/AIO (adjuvant imatinib in GIST)SSGXVIII/AIO (adjuvant imatinib in GIST) reported
RFS HR 0.
- 2012MilestoneSSGXVIII/AIO (adjuvant imatinib in GIST)SSGXVIII: 3-year adjuvant imatinib; pazopanib approved (PALETTE)
A milestone in how this cancer is treated.